| Literature DB >> 29589381 |
Sinthia Zrinka Bosnic-Anticevich1.
Abstract
When it comes to the use in inhalers in the management of chronic obstructive pulmonary diseases, there are many options, considerations and challenges, which health care professionals need to address. Considerations for prescribing and dispensing, administering and following up, education, and adherence; all of these factors impact on treatment success and all are intrinsically linked to the device selected. This review brings together relevant evidence, real-life data and practice tools to assist health care professionals in making decisions about the use of inhalers in the management of chronic obstructive pulmonary diseases. It covers some of the key technical device issues to be considered, the evidence behind the role of inhalers in disease control, population studies which link behaviors and adherence to inhaler devices as well as practice advice on inhaler technique education and the advantages and disadvantages in selecting different inhaler devices. Finally, a list of key considerations to aid health care providers in successfully managing the use of inhaler devices are summarized. Copyright©2018. The Korean Academy of Tuberculosis and Respiratory Diseases.Entities:
Keywords: Device; Inhaler; Pulmonary Disease, Chronic Obstructive
Year: 2018 PMID: 29589381 PMCID: PMC5874147 DOI: 10.4046/trd.2017.0119
Source DB: PubMed Journal: Tuberc Respir Dis (Seoul) ISSN: 1738-3536
Summary of strengths and weakness of pressurized metered dose inhalers (pMDIs), dry powder inhalers, and soft mist inhalers
| Summary | |
|---|---|
| Pressurized metered dose inhalers | pMDIs deliver a predefined dose of medication in the form of a fast and short-lasting aerosol |
| Strengths | Compact and portable |
| Dose consistency | |
| Multidose (>10 doses) | |
| Can be used with a wide range of inhaler therapies | |
| Not affected by humidity | |
| Weaknesses | Rapid-moving and short-lasting aerosol |
| Contains propellant | |
| Low lung deposition/high oropharyngeal deposition | |
| ‘Cold freon’ effect | |
| Requires good coordination of actuation and inhalation | |
| The majority of devices lack a dose counter | |
| Dry powder inhalers (DPIs) | DPIs require energy from the patient's inhalation to disperse a powder formulation from the device into smaller particles |
| Strengths | Compact and portable |
| Convenient (multidose) | |
| Breath-actuated | |
| No propellants | |
| Minimal coordination required | |
| May have a dose counter | |
| Weaknesses | Passive inhaler |
| The flow rate to generate the fine particle fraction and release the drug is dependent on the internal resistance of the device, and varies between DPIs | |
| Moisture-sensitive | |
| High oropharyngeal deposition | |
| Dose inconsistency | |
| For low-resistance DPIs, the high inspiratory flow required to disaggregate the drug can result in high oropharyngeal impaction and low lung deposition | |
| Soft mist inhalers | Inhalers (Respimat) that produce a soft mist with low velocity, long-lasting aerosol |
| Strengths | Active inhaler |
| Compact and portable | |
| Easier to coordinate than pMDIs | |
| Low inspiratory flow required | |
| High lung deposition/low oropharyngeal deposition | |
| High fine particle fraction | |
| Consistent dosing (active inhaler) | |
| Multi-dose (1-mo supply) with dose indicator | |
| No propellant | |
| Not affected by humidity | |
| Weaknesses | Requires some coordination of actuation and inhalation |
| Requires priming before first use | |
| Require hand grip strength for loading the cartridge, an issue for patients with weak manual strength | |
| If unused for a period of time, additional priming is required | |
| Inhaler must be discarded once all doses are delivered or 3 mo after preparation for the first use |
Figure 1Pathway to device selection. Modified from Dekhuijzen et al. Respir Med 2013;107:1817–21, according to the Creative Commons license63. pMDI: pressurized metered dose inhaler; DPI: dry powder inhaler.